Auro Laboratories Limited wishes to inform that Company has received World Health Organization - Good Manufacturing Practices (WHO-GMP) Certifcate from Food & Drug Administration.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 17.1 pts more than Nifty Microcap 250 and 17.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Auro Laboratories has received the WHO-Good Manufacturing Practices (WHO-GMP) Certificate for its Active Pharmaceutical Ingredients (Bulk Drugs) manufacturing unit in MIDC Tarapur, Maharashtra. The certification was granted by the Food & Drug Administration, Maharashtra after a successful WHO inspection. The certificate is valid until September 30, 2028, giving the company about three years of compliance status for this facility. This is a quality and regulatory compliance milestone rather than a specific order or revenue event. WHO-GMP certification is typically required for supplying APIs and pharmaceutical products to regulated international markets.
Positively positions the company to pursue export opportunities and tenders in WHO-regulated markets, potentially expanding its customer base. The certification itself is an operational milestone, so the immediate stock impact may be modest, but it strengthens the company's credibility in the global API space.